Background and purpose: HbA1c is a measuring tool to indicate average blood glucose over two to three months and is slightly affected by stress hyperglycemia during STEMI. The aim of this study was to evaluate the relationship between HbA1c and one month mortality and morbidity in STEMI patients and also in diabetic and non-diabetic males and females, and hypertensive patients. Materials and methods: Four hundred and seventy patients with STEMI were divided into two groups group A with HbA1c<6.2 and group B with HbA1c≥6.2. Then one month mortality and morbidity rate of STEMI and also complications were assessed among these patients and the subgroups. Results: We found that one month mortality rate of STEMI did not increase significantly when HbA1c exceeded 6.2. In contrast the rate of RBBB and EF<50% increased significantly. Conclusion: HbA1c level was not an important predictor of mortality in STEMI patients. This was also true for subgroups. HbA1c level was potentially a risk factor for the occurrence of RBBB and EF<50%.

Keywords: HbA1c, STEMI, mortality rate

Full-Text [PDF 285 kb]   (2790 Downloads)